Literature DB >> 19091522

Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005.

Shio-Shin Jean1, Po-Ren Hsueh, Wen-Sen Lee, Hou-Tai Chang, Ming-Yuan Chou, Ing-Shen Chen, Jen-Hsien Wang, Chen-Fu Lin, Jainn-Ming Shyr, Wen-Chien Ko, Jiunn-Jong Wu, Yung-Ching Liu, Wen-Kuei Huang, Lee-Jene Teng, Cheng-Yi Liu.   

Abstract

A nationwide surveillance of the antimicrobial susceptibilities of glucose non-fermentative Gram-negative bacteria isolates was conducted from 1 September 2005 to 30 November 2005 in Taiwan. A total of 456 isolates were recovered from patients hospitalised in the Intensive Care Units (ICUs) of ten major teaching hospitals. Rates of resistant pathogens, such as ciprofloxacin-resistant Pseudomonas aeruginosa (19%) and imipenem-resistant Acinetobacter baumannii (25%), were higher than those reported in 2000 (8% and 22%, respectively). Increased rates of isolates with resistant phenotypes correlated with prolonged length of ICU stay (48h to <or=7 days vs. >7 days) for ceftazidime-non-susceptible P. aeruginosa (20.0% and 29.7%, respectively), imipenem-non-susceptible P. aeruginosa (4.0% and 13.5%, respectively) and imipenem-non-susceptible A. baumannii (15.4% and 29.8%, respectively), but not for ciprofloxacin-resistant P. aeruginosa. Alarming rates of emergence of extensively drug-resistant (XDR) A. baumannii (15%) and XDR P. aeruginosa (1.8%) were found, particularly among those isolates that were not susceptible to tigecycline and colistin. Interhospital dissemination of some clones of XDR A. baumannii in different ICUs was also noted. This study illustrates the crucial nature of continuous nationwide surveillance of resistant pathogens and implementation of effective strategies for ICU infection control and antibiotic restriction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091522     DOI: 10.1016/j.ijantimicag.2008.08.026

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  Loss of mitochondrial protein Fus1 augments host resistance to Acinetobacter baumannii infection.

Authors:  M Indriati Hood; Roman Uzhachenko; Kelli Boyd; Eric P Skaar; Alla V Ivanova
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

2.  Comparison of genospecies and antimicrobial resistance profiles of isolates in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex from various clinical specimens.

Authors:  Ni Tien; Bang-Jau You; Hui-Lan Chang; Hsiu-Shen Lin; Chin-Yi Lee; Tung-Ching Chung; Jang-Jih Lu; Chao-Chin Chang
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

3.  Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes.

Authors:  Teena Chopra; Dror Marchaim; Reda A Awali; Amar Krishna; Paul Johnson; Ryan Tansek; Khawar Chaudary; Paul Lephart; Jessica Slim; Jatinder Hothi; Harris Ahmed; Jason M Pogue; Jing J Zhao; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

4.  Imaging mass spectrometry for assessing temporal proteomics: analysis of calprotectin in Acinetobacter baumannii pulmonary infection.

Authors:  Jessica L Moore; Kyle W Becker; Joshua J Nicklay; Kelli L Boyd; Eric P Skaar; Richard M Caprioli
Journal:  Proteomics       Date:  2013-07-24       Impact factor: 3.984

5.  In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART Programme.

Authors:  S-S Jean; P-R Hsueh; W-S Lee; H-T Chang; M-Y Chou; I-S Chen; J-H Wang; C-F Lin; J-M Shyr; W-C Ko; J-J Wu; Y-C Liu; W-K Huang; L-J Teng; C-Y Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-27       Impact factor: 3.267

6.  Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration.

Authors:  M Indriati Hood; Brittany L Mortensen; Jessica L Moore; Yaofang Zhang; Thomas E Kehl-Fie; Norie Sugitani; Walter J Chazin; Richard M Caprioli; Eric P Skaar
Journal:  PLoS Pathog       Date:  2012-12-06       Impact factor: 6.823

7.  Antimicrobial Resistance Mechanisms and Virulence of Colistin- and Carbapenem-Resistant Acinetobacter baumannii Isolated from a Teaching Hospital in Taiwan.

Authors:  Noor Andryan Ilsan; Yuarn-Jang Lee; Shu-Chen Kuo; I-Hui Lee; Tzu-Wen Huang
Journal:  Microorganisms       Date:  2021-06-14

8.  Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program.

Authors:  Shu-Chen Kuo; Shan-Chwen Chang; Hui-Ying Wang; Jui-Fen Lai; Pei-Chen Chen; Yih-Ru Shiau; I-Wen Huang; Tsai-Ling Yang Lauderdale
Journal:  BMC Infect Dis       Date:  2012-08-28       Impact factor: 3.090

Review 9.  Antimicrobial resistance in Asia: current epidemiology and clinical implications.

Authors:  Cheol-In Kang; Jae-Hoon Song
Journal:  Infect Chemother       Date:  2013-03-29

10.  Risk factors for healthcare-associated extensively drug-resistant Acinetobacter baumannii infections: a case-control study.

Authors:  Ming-Chin Chan; Sheng-Kang Chiu; Po-Ren Hsueh; Ning-Chi Wang; Chih-Chien Wang; Chi-Tai Fang
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.